Basilea Pharmaceutica AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPMUF research report →
About the company
Basilea Pharmaceutica AG is a biopharmaceutical company already generating revenue from its products, which are designed to fulfill medical needs in the challenging areas of cancer (oncology) and infectious diseases (anti-infectives). The company's product portfolio includes Cresemba, an azole antifungal drug administered intravenously or orally. This medication is approved for treating invasive aspergillosis and mucormycosis in both the United States and the European Union.
- CEO
- David Veitch
- IPO
- 2015
- Employees
- 164
- HQ
- Allschwil, CH
Price Chart
- Market Cap
- $746.00M
- P/E
- 20.52
- P/S
- 3.72
- P/B
- 5.18
- EV/EBITDA
- 17.46
- Div Yield
- 0.00%
- Gross Margin
- 74.32%
- Op Margin
- 21.94%
- Net Margin
- 17.90%
- ROE
- 27.95%
- ROIC
- 14.94%
- Revenue
- $232.51M · 11.49%
- Net Income
- $40.22M · -48.17%
- EPS
- $3.29 · -48.75%
- Op Income
- $51.62M
- FCF YoY
- -18.01%
- 52W High
- $74.00
- 52W Low
- $47.50
- 50D MA
- $67.99
- 200D MA
- $62.85
- Beta
- 0.41
- Avg Volume
- 13
Get TickerSpark's AI analysis on BPMUF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BPMUF coverage
Recent articles, reports, and earnings notes.
No research on BPMUF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BPMUF report →Similar companies
Peers in the same neighborhood.